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Translocation t(4;11)(q21;q23) leading to formation of MLL-AF4 fusion gene is found in about 10% of newly diagnosed B-cell
acute lymphoblastic leukemia (ALL) in adult patients. Patients expressing this chromosomal aberration present typical biological,
immunophenotypic, and clinical features. This form of leukemia is universally recognized as high-risk leukemia and treatment
intensiﬁcation with allogeneic hematopoietic stem cell transplantation (HSCT) in ﬁrst complete remission (CR) could be a
valid option to improve prognosis, but data obtained from the literature are controversial. In this review, we brieﬂy describe
pathogenetic, clinical, and prognostic characteristics of adult t(4;11)(q21;q23)/MLL-AF4 positive ALL and provide a review of the
clinical outcome reported by the most important cooperative groups worldwide.
1.Introduction
The chromosomal translocation occurring between the band
21 of the long arm of chromosome 4 and band 23 of the long
armofchromosome11[t(4;11)(q21;q23)]andleadingtothe
generation of the fusion gene MLL-AF4 is one of the most
recurrent chromosomal aberrations observed in acute lym-
phoblastic leukemia (ALL). However, a diagnosis of t(4;11)
(q21;q23)/MLL-AF4 positive ALL in adult patients is a rare
event, considering the relative low incidence of ALL in adult
population. In spite of its rarity, this form of leukemia is of
clinical interest because it is universally recognized as a uni-
que and separate biological entity with characteristic im-
munophenotypic and clinical features. Here, we brieﬂy des-
cribe pathogenetic, clinical, and prognostic characteristics
of adult t(4;11)(q21;q23)/MLL-AF4 positive ALL and review
the therapeutic approaches proposed for its treatment by
most of the important cooperative groups worldwide.
2.Pathogenetic Aspects of
MLL Rearrangements
Mixed-Lineage-Leukemia (MLL) gene is one of the most fre-
quently involved genes in hematologic malignancies, in par-
ticular in some forms of acute leukemia, both lymphoblas-
tic and myeloid; the Atlas of Genetics Oncology (http://atlas-
geneticsoncology.org/Anomalies/11q23ID1030.html)r e -
ports 73 recurrent translocations and 54 chromosome loci as
partner site of reciprocal translocations involving the band
23 of the long arm of chromosome 11 (11q23), in particular
MLL gene. The MLL gene, located on 11q23, is the mam-
malian counterpart of Drosophila trithorax that plays an
essentialroleinpositiveregulationofgeneexpressioninearly
embryonic development and hematopoiesis (i.e., Polycomb
and Hox genes) [1]. MLL encodes a 500kD protein that con-
tains multiple conserved functional domains including three
AT hooks (near the N-terminal portion of MLL), four cen-
tral zinc ﬁnger domains, and 210-aminoacid C-terminal SET
domain. The last is responsible for its histone H3 lysine 4
(H3K4) methyltransferase activity which mediates chroma-
tin modiﬁcations associated with epigenetic transcriptional
activation [2]. MLL localization and stabilization depend on
aproteolytic post-translational processactivatedbytaspase1,
a specialized protease cleaving the MLL protein into N-ter-
minal 320kD (MLLn) and C-terminal 180kD (MLLc)f r a g -
ments.Thesefragmentsareresponsibleforthetranscription-
al regulation of speciﬁc target genes, including many of2 Advances in Hematology
the HOX genes, that are key regulators of normal and mali-
gnant hematopoiesis [3].
Several chromosomal aberrations can occur to the MLL
gene, with two main action mechanisms: reciprocal translo-
cations, resulting in in-frame fusion transcripts with various
partner genes, and partial tandem duplication (PTD) of gene
[4]. MLL gene translocations result in a chimeric fusion
protein in which the N-terminal portion of the MLL gene is
fused to the C-terminal portion of the gene fusion partners;
the methyltransferase domain of MLL (SET domain) is in-
variably lost in MLL-fusion protein. These fusion genes may
alter the normal cellular proliferation and diﬀerentiation
processes, favoring leukemogenesis [5]. Several studies de-
monstrated that 11q23 is susceptible to double strand breaks
resultingfrominhibitionoftopoisomeraseII[6];thisspeciﬁc
susceptibility can explain the high incidence of MLL aberra-
tions occurring in secondary acute leukemias (i.e., therapy-
related acute myeloid leukemia, especially after treatment
with topoisomerase II inhibitors). Two distinct breakpoint
cluster regions in the MLL gene could be distinguished: bcr1
and bcr2. Bcr1 encompasses approximately 3.5kb from the
startofintron8uptotheﬁrstapproximately600bpofintron
11, and bcr2 included approximately 200bp immediately at
the 5’ boundary of exon 12. Ninety-ﬁve percent of breaks
occurred within these 2 regions [7].
Recently published data have revealed 104 diﬀerent MLL
rearrangements of which 64 translocation partner genes are
now characterized [8]. It is worth noting that all partner
proteins are nuclear localization signals and play function
as potent transcriptional factors. The most common fusion
partner genes of MLL, reported in order of frequency, are
AF4,AF9,ENL,AF10,AF6,ELL,andAF1P.Interestingly,dis-
tinct MLL fusion partners suggest a possible role in the tro-
pism of the leukemia because certain partner proteins not
only convert MLL to an oncogenic fusion protein but also
direct the lineage susceptibility for transformation; MLL-
AF4 expressing leukemias are mainly diagnosed as pro-B
ALL in both pediatric and adult patients, whereas fusion
partners AF9, AF6,o rAF10 are common in myelomonocytic
or monoblastic acute myeloid leukemia subtypes [9]. It is
diﬃcult to imagine how unrelated proteins create oncogenic
MLLchimerasthattransformhaematopoieticcellsbysimilar
mechanism.SeveralstudiessuggestthatMLLfusionpartners
interact with a complex of proteins, that stimulate the acti-
vityofRNA-polymeraseII,leadingtogenesderegulationand
transformation in leukemia [10, 11]. These proteins include
PTEFb and DOTL1. PTEFb is a dimer of CDK9 and cyclin
T1 that phosphorylates the C-terminal domain of RNA poly-
merase II (CTD) for eﬃcient transcription elongation [12].
AF4, in association with ENL and AF9, stimulates activity of
the RNA polymerase II (RNA pol II)-CTD kinase pTEFb and
the histone methyltransferase DOT1L show that fusing the
pTEFb-interactingdomainofAF4familymemberstoMLLis
necessary and suﬃcient for leukemic transformation, while
DOT1L is not suﬃcient [13]. Other studies suggest that
DOT1L methyltransferase activity is crucial for Hox gene de-
regulation and transformation seen in leukemias with MLL
rearrangements. (Table 1)[ 10–14].
However, these experimental models recapitulate MLL-
rearranged AML and the development of models about
MLL-fusion mediated ALL has proven more diﬃcult, so
the exact mechanism by which the translocation t(4;11)(q21;
q23) leads to leukemogenesis is incompletely characterized.
An early favored hypothesis was that haploin suﬃciency
of the MLL locus combined with a dominant-negative eﬀect
of the oncogenic fusion gene could lead to the loss of key
MLL functions [15]. For describing MLL-fusion-mediated
ALL, several mouse models and molecular experimental sys-
tems have been so far engineered. However, the ﬁrst engi-
neered mouse models have resulted in myelodysplasia or
mature B-cell lymphomas. In fact, Chen and collaborators in
amurine Mll-Af4knock-in model observed thedevelopment
of a mixed lymphoid/myeloid hyperplasia or mature B-cell
lymphomas (after prolonged latency), suggesting that Mll-
Af4-induced lymphoid/myeloid deregulation alone is in-suf-
ﬁcient to produce malignancy [16]. Using also invertor tech-
nology for performing a conditional expression of Mll-Af4
in lymphoid lineage in mice, Metzler et al. found the deve-
lopment of mature lymphoproliferative disease, demon-
strating that the stem cell in which the MLL fusion protein
is expressed is not an uncommitted progenitor and that
MLL-AF4 inﬂuences the phenotype of the tumour when
expressed within cells of the lymphoid lineage [17]. Further
studies in murine systems suggested an active role for MLL
partners in leukemogenesis, through a dysregulation of gene
expressioninleukemiccells.Infact,Krivtsovetal.usingcon-
ditional Mll-Af4 knock-in mouse (in which the MLL-AF4
fusionproductis expressedwithinthecontext ofthe endoge-
nous MLL locus) observed that the expression of Mll-Af4
in lymphoid cells leads to in vitro leukemic transformation.
It was associated with an overexpression of some genes, as
HoxA9 and Meis1, observed in ALL and caused by an high
H3K4 methyltransferase activity. Since the methyltransferase
domain of MLL is invariably lost in MLL-fusion proteins, in-
cluding MLL-AF4, it was found that MLL-AF4 recruits
DOT1L to MLL target genes, and promotes methylation sti-
mulating transcriptional elongation of genes that are nor-
mally primed but not fully transcribed [18]. Using a murine
retroviral model, Faber et al. demonstrated that the sup-
pression of HoxA9 causes apoptosis in cell expressing an Mll-
fusion, suggesting that Hox genes are necessary for survival
of leukemic cells [19].
In addition, using microarray technology, it was demon-
strated that the MLL-rearrangement cells present an upreg-
ulation of HOX genes (HOXA9, HOXA10, and HOXC6,
together with the MEIS1 HOX cofactor), emphasizing the
centralroleofderegulationofthisclassofgenesinthepatho-
genesis of MLL-rearrangement ALL [20]. Fernando and col-
laborators showed that HOX gene overexpression in B and
T-lineage leukemias with MLL translocations, cause a block
at an early stage of cell diﬀerentiation and an aberrantly in-
c r e a s e dc e l ls u rvi v a l[ 21]. How MLL gene rearrangement up-
regulates HOX genes is unknown, but two prevalent models
have been established: transactivation and dimerization, that
are not mutually exclusive. The activation of target genes by
MLL fusions can also be mediated through histone modi-
ﬁcations and methylation, suggesting a crucial role ofAdvances in Hematology 3
Table 1: The most common fusion partner genes of MLL: locations and functions.
Partner gene Location Function
AF4 4q21 Nuclear Leads to RNApol-II activation and to transcriptional elongation
AF9 9p22 Nuclear In association with ENL, DOT1L, and AF4, activator of RNApol-II kinase p-TEFb
ENL 19p13.3 Nuclear Elongation factor. In association with AF9, DOT1L and AF4 activator of RNApol-II kinase p-TEFb
AF10 10p12 Nuclear Transcriptional factor
ELL 19p13.1 Nuclear Elongation factor interacts with a nuclear protein related to AF4
AF6 6q27 Cytoplasmatic Multi-domain protein involved in signaling and organization of cell junctions during embryogenesis
AF1P 1p32 Cytoplasmatic Part of the EGFR pathway, involved in receptor-mediated endocytosis of EGF
p-TEFb: positive transcription elongation factor b. p-TEFb phosphorylates serine residues of the carboxy-terminal domain of RNApol-II; RNApol-II: RNA
polymerase II; CTD: carboxy-terminal domain kinase; DOT1L: DOT1-like, histone H3 methyltransferase; EGFR: epidermal growth factor receptor; EGF:
epidermal growth factor.
epigenetic regulation in oncogenesis [22]. Several studies de-
monstrated that the dimerization of the MLL N-terminal
portion is necessary for leukemogenic transformation, be-
cause it immortalizes hematopoietic cells and imposes a
reversible block on diﬀerentiation; the analysis of transient-
ly transfected cells showed that dimerization of the fusion
protein activated transcription (nearly 250-fold) in a dose-
dependent manner. In addition, this mechanism causes a
resistance to cell degradation by speciﬁc cell-cycle ligase in
MLL fusion protein [23]. Dimerization of MLL N-terminal
portion of MLL gene converts it into a transcriptional trans-
activator,leadingtoupregulationofHOXproteins,especially
HOXA9 and MEIS1, that are overexpressed in a wide variety
of some leukemias (T-ALLs, acute myeloid leukemia and
biphenotypic leukemia) and that act, at least partially,
through activation of the proto-oncogene MYB [24]. In
general, HOX transcription factors are not only master con-
trols of embryonic development but they also direct normal
hematopoietic diﬀerentiation. HOX expression is high in
stem cells and early precursors and needs to be downregu-
lated for maturation. Therefore, a continuous ectopic HOX
expression willblock diﬀerentiation andcreatearapidly pro-
liferating preleukemic precursor pool. Obviously, other
mechanisms are involved in the pathogenesis of MLL rear-
ranged ALL, suggesting a crucial role of epigenetic modiﬁca-
tion of chromatin region connected with MLL translocation.
For example, Gessner and collaborators showed a link bet-
ween MLL/AF4 and telomerase, a key element of both nor-
mal and malignant self-renewal. Moreover, they examined
the inﬂuence of MLL/AF4 on the expression of TERT (telo-
merase reverse transcriptase) coding for the telomerase pro-
tein subunit, and subsequently telomerase activity in t(4;11)-
positive ALL, showing that MLL/AF4 through the expression
of a speciﬁc gene, such as HOXA7 unbalanced TERT expres-
sion and accelerated telomere shortening [25]. In addition,
MLL-rearrangedALLisfrequentlyassociatedwithanoverex-
pression of fms-related tyrosine kinase 3 (FLT3), that seems
contributing, at least in part, to resistance to chemotherapy
[26].
3.ClinicalFeatures
3.1. Incidence. The incidence of t(4;11)(q21;q23)/MLL-AF4
positive ALL has a characteristic bimodal age distribution
with a major peak in early infancy, occurring in over 50%
ALL cases in infants aged less than 6 months, in 10–20% of
older infants, in about 2% of children, and in almost 10% of
adults [27–29].
The presence of a translocation t(4;11)(q21;q23) or a
fusiongeneMLL-AF4isdetectedinalmost10%ofnewlydia-
gnosed adult B-cell ALL and in about 30–40% of pro-B ALL
subtypes [30–35].
In the international clinical trial of the Medical Research
Council (MRC) UKALLXII and the Eastern Cooperative
Oncology Group (ECOG) E2993, cytogenetic data from a
total of 1522 adult patients with newly diagnosed ALL were
centrallyreviewedof1003casesinwhichcytogeneticanalysis
was successfully performed; 69 patients had a translocation
involving the MLL gene located at 11q23 and the majority of
these (n = 54) had a t(4;11)(q21;q23), with a global estimate
incidence of 6.9% and 5.4% respectively [30].
3.2. Immunophenotype and Morphology. In the vast majority
of t(4;11)(q21;q23)/MLL-AF4 positive ALL, leukemic blasts
haveatypicalantigenicproﬁle,suggestingapostulatedorigin
from the multipotent or very early CD10neg B-progenitor
cellswithafrequentcoexpressionofmyeloidantigens:CD19,
CD22, cyCD79a, HLA-DR, TdT, and CD34 are frequent-
ly and strongly expressed, CD24 and cyIgM are negative or
weakly expressed, CD20 is rarely expressed whereas CD10 is
always negative. CD15 and CD65 myeloid antigens are fre-
quentlyexpressedbutCD13andCD33arenegative.Thisim-
munophenotypicpatterncanbealsousedtopredictwithrel-
ative precision the presence of a translocation between chro-
mosome 4 and 11, and the typical and aberrant expression of
somemyeloidantigenscanbeusefulformonitoringminimal
residual disease (MRD) during the treatment, in order to
establish need for treatment intensiﬁcation [40, 41]. More
studies have so far described the strong association between
a CD10neg B-cell precursor immunophenotype (pro-B-cell
ALL) and abnormalities of band 23 of chromosome 11,
particularly in infant ALL but also in adult patients [34, 42].
Recently,ithasbeenobservedthatthechondroitinsulfate
proteoglycan neural-glial antigen 2 (NG2) is frequently ex-
pressed in ALL with MLL rearrangements and is relatively,
though not absolutely, speciﬁc. In particular, Burmeister and
collaborators showed NG2 expression in 184 newly diag-
nosed patients with CD10 negative B-cell ALL, studied4 Advances in Hematology
Table 2: Cytogenetic molecular classiﬁcation of adult ALL based on more recently published data.
Risk group Chromosomal/molecular aberrations 5y-DFS 5y-OS
STANDARD-RISK
Isolated 9p/p15-p16 deletions
High hyperdiploidy
Normal karyotype/no molecular aberrations
35–68% 48–80%
INTERMEDIATE-RISK
del(6q)
Trisomy of chromosome 21
Trisomy of chromosome 8
t(1;19)/E2A-PBX
37–51% 35–40%
HIGH-RISK
t(9;22)/BCR-ABL
t(4;11)/MLL-AF4
11q23 MLL rearrangements
Monosomy of chromosome 7
Low hypodiploidy/near triploidy
Complex karyotype
High BAALC expression
Aberrations of IKZF1 gene
10–52% 15–35%
CR: complete remission; 5y-DFS: 5 years disease-free survival; 5y-OS: 5 years overall survival.
Table 3: Risk stratiﬁcation in adult ALL (adapted from [36]a n d
[37]).
Parameter Favourable Unfavourable
Age (years) 18–35 >35
WBC count <30 ×109/L >30 ×109/L(B-cell)
>100 ×109/L(T-cell)
Immunophenotype Thymic
Pro-T, Mature T
Pro-B
CD20 expression
Cytogenetic/molecular
data
del(9p)
High
hyperdiploidy
t(9;22)/BCR-ABL
t(4;11)/MLL-AF4
Low hypodiploidy
Complex karyotype
High BAALC expression
Aberrations of IKZF1
gene
Time to CR Early Late (>3-4 weeks)
MRD after induction
therapy
Negative
(<10−4) Positive (>10−4)
WBC: white blood count; CR: complete remission; MRD: minimal residual
disease; BAALC: brain and acute leukemia cytoplasmic gene; IKZF1:
IKAROS family zinc ﬁnger 1 gene.
in place of showed NG2 expression in 94% of MLL-AF4
positive patients, in 87% of patients with other MLL rear-
rangements and only in 15% of MLL negative patients, sug-
gesting the relative speciﬁcity of this marker in predicting
aberration of the MLL gene [7, 43]. Concerning morphology
features, no speciﬁc morphologic pattern is associated to the
t(4;11)(q21;q23) ALL, but many cases are diagnosed as L2
French-American-British (FAB) subtype.
3.3. Clinical Presentation. The presence of t(4;11)(q21;q23)
with expression of the fusion gene MLL-AF4 characterizes a
subset of ALL with aggressive clinical features. These patients
at diagnosis frequently have an elevated white blood count
(WBC),massivehepatosplenomegalyorlymphadenomegaly,
higher LDH values, and frequent Central Nervous System
(CNS) involvement, with a poor clinical outcome both in
infants and in adults [29, 44]. In contrast to other forms of
ALL, these patients are characterized by a frequent presence
of disseminated intravascular coagulation (DIC) at diagno-
sis: Vey and collaborators have described 14 cases of DIC in
34 patients with t(4;11)(q21;q23)/MLL-AF4 positive ALL at
diagnosis (41%), a percentage signiﬁcantly higher compared
to other patients enrolled in the LALA-94 cooperative study
of the France-Belgium Group for Lymphoblastic Acute
Leukemia in Adults. In this study however, patients with this
chromosomal aberration had a similar incidence of organo-
megaly and of CNS involvement compared with other forms
of ALL [38].
The clinical trials 03/87 and 03/89 of the German Multi-
center study group for treatment of adult Acute Lympho-
blastic Leukemia (GMALL) have shown that patients with
t(4;11)(q21;q23)ALLatdiagnosishadahighermedianWBC
count(168.3×109/L),amalepredominance,increasedCD65
expression, a younger age predominance, and a lower inci-
dence of initial infections than other cytogenetic subgroups
of pro-B ALL. However, no diﬀerences were observed for
thepresenceofhepatosplenomegaly,initialbleeding,haemo-
globin level at diagnosis, and also for the prevalence of CNS
involvement [33]. More recent data from the same coopera–
tive study group conﬁrmed only some of these ﬁndings. In
184 adult patients with pro-B CD10neg ALL enrolled in two
consecutive clinical trials (GMALL 6/99 and 7/03), MLL-
AF4positivepatientswerecharacterizedbyamoreaggressive
clinicalpresentation,withhigherWBCatdiagnosis(median:
141×109/L),butnodiﬀerencewasreportedforageatpresen-
tation between MLL/AF4 positive and negative patients [7].
In the Gruppo Italiano Malattie EMatologiche dell’Adulto
(GIMEMA)0496protocol,24patientspresentedatdiagnosis
a t(4;11)(q21;q23)/MLL-AF4 positive ALL. These patients
had a median age of 39 years with no sex prevalence, more
than 50% had at diagnosis a WBC number higher than
50 × 109/L; all patients presented a B-cell phenotype and
none of these patients were characterized by the expressionAdvances in Hematology 5
Table 4: Clinical outcome of t(4;11)(q21;q23)/MLL-AF4 positive ALL in diﬀerent cooperative trials worldwide.
Study Year No. Patients
(Age)
% of patients
t(4;11)/MLL-
AF4
positive
Treatment strategy
% of patients
undergoing
HSCT
intensiﬁcation
Global outcome
(OS and DFS)
t(4;11)/MLL-AF4
positive ALL
outcome
MRC
UKALLXII/ECOG
E2993 [30]
2007 1522 (15–65) 5.4%
Intensiﬁcation with
HSCT for Ph+ and
for patients younger
than 50 years with
HLA-matched family
donor
21% 5y-DFS: 38%(a)
5y-OS: 43%(a)
5y-DFS: 24%
5y-OS: 24%
GIMEMA
LAL0496 [32] 2003 403 (15–60) 6%
Intensiﬁcation with
HSCT only for Ph+
patients
20% 5y-DFS: 31%
5y-OS: 31%
5y-CCR: 15%
5y-OS: 23%
GMALL 04/87–89
[33] 1998 611 (15–65) 3.6%
Intensiﬁcation with
HSCT for younger
high risk patients
with HLA-matched
family donor
na 5y-CCR: 45%
5y-OS: 40%
5y-CCR: 40%
5y-OS: 41%
NILG-ALL 09/00
[35] 2009 280(16–65) 7.3%
Intensiﬁcation with
HSCT in patients
MRD+ after
consolidation
31% 5y-OS: 34% 5y-OS 27%(b)
LALA94 [38] 2006 922 (15–55) 6%
Intensiﬁcation with
HSCT in high risk
and CNS+ patients
19% 5y-DFS: 30%
5y-OS: 33%
5y-DFS: 30%
5y-OS: 38%
GRAALL-2003
[34] 2009 225 (15–60) 9.5%
All patients were Ph
negative.
Intensiﬁcation with
HSCT in high risk
patients
31% 3.5y-DFS: 55%
3.5y-OS: 60%
3.5y-DFS: 52%(b)
—
PETHEMA
ALL-93 [39] 2005 222 (15–50) 4%
Intensiﬁcation with
HSCT for patients
with HLA-matched
family donor
31% 5y-DFS: 35%
5y-OS: 34% Same results
(a)data relative at Ph negative patients; (b)data relative at clinical outcome of all non-Ph+ high-risk patients evaluated, including t(4;11)/MLL-AF4 positive
patients. OS: overall survival; DFS: disease-free survival; CCR: survival in continuous complete remission; CR: complete remission; HSCT: allogeneic
hematopoietic stem cell transplantation; Ph+: Philadelphia-positive patients; MRD: minimal residual disease; CNS: central nervous system; MRC: British
Medical Research Council; ECOG: Eastern Cooperative Oncology Group; GIMEMA: Gruppo Italiano Malattie EMatologiche dell’Adulto; GMALL: German
Multicenter study group for treatment of adult Acute Lymphoblastic Leukemia; NILG: Northern Italy Leukemia Group; LALA: France-Belgium Group for
Lymphoblastic Acute Leukemia in Adults; GRAALL: Group for Research on Adult Acute Lymphoblastic Leukemia (including the former France-Belgium
Group for Lymphoblastic Acute Leukemia in Adults, the French Western-Eastern Group for Lymphoblastic Acute Leukemia, and the Swiss Group for Clinical
Cancer Research); PETHEMA: Programa para el Estudio del la Terapeutica en Hemopat´ ıa Maligna; na: not available.
of CD13 and CD33 myeloid antigens compared to the other
cytogenetic-molecular subgroups [31]. Recently Cimino and
collaborators describe the largest cohort of patients with
MLL-AF4 positive ALL, analyzing the clinical course of 46
adult patients enrolled into 2 successive multicenter clinical
trials (GIMEMA 0496 and LAL 2000): all cases presented a
pro-B immunophenotypic pattern; the median age of pa-
tients was39yearswithoutsexpredominance, WBCcountat
diagnosis was lower respect to previously described series
with a median value of 60 × 109/L and the median haemo-
globin value and platelet counts were 9g/dL and 33 × 109/L,
respectively [45].
3.4.ClinicalOutcomeandPrognosticConsiderations. Cytoge-
neticandmolecularanalysisofleukemiccellsatdiagnosisare
cornerstones for the prognostic stratiﬁcation of ALL patients
at onset of disease because they are independent factors in
predicting clinical outcome of patients. Stratiﬁcation of ALL
patients according to cytogenetic and molecular characteri-
zationhelpsestablishthebestpostremissiontherapyforindi-
vidual patients, including the possibility of consolidation
treatment intensiﬁcation and allogeneic hematopoietic stem
cell transplantation (HSCT).
T h ep r e s e n c eo f1 1 q 2 3c h r o m o s o m a la b e r r a t i o n sw i t h
alteration of MLL gene is generally recognized as an unfav-
ourableprognostic characteristic ofsomeformsofALL.[46–
49]. A t(4;11)(q21;q23)/MLL-AF4 positive ALL is generally
considered as a high risk leukemia, characterized by a poor
clinical outcome respect to other cytogenetic risk groups.
Based on more recently published data, adult ALL patients
can be separated in three diﬀerent prognostic groups
according to speciﬁc cytogenetic and molecular aberrations6 Advances in Hematology
found at onset of disease: a standard, an intermediate, and
an high-risk group, including t(4;11)(q21;q23)/MLL-AF4
positive patients (Table 2). Moreover, in several studies it
has been demonstrated that cytogenetic-molecular risk and
WBC count at diagnosis were the main prognostic factor
inﬂuencing DFS and OS in adult ALL patients. However,
despite the great relevance of cytogenetic and molecular
aberrations on clinical outcome of the adult ALL patients, a
correct risk stratiﬁcation useful to modulate the intensity of
treatment needs to be integrated with other clinical baseline
data and with important dynamic parameters, such as the
timing of reaching morphologic complete remission (CR)
and the quantiﬁcation of MRD after induction or consolida-
tion therapy using immunophenotypic or molecular meth-
ods (Table 3).
Table 4 summarizes the most relevant studies performed
by cooperative multicenter groups worldwide in adult ALL,
showing clinical outcome of patients t(4;11)(q21;q23)/MLL-
AF4 positive. Due to the relatively low incidence of this chro-
mosomal aberration, not all these studies show speciﬁc data
aboutt(4;11)(q21;q23)/MLL-AF4positivepatients,butfocus
more generally on non-Philadelphia-positive high-risk pa-
tients (i.e., age >30 years, WBC count >30×109/L, t(4;11)
(q21;q23)/MLL-AF4 positive patients, t(1;19)/E2A-PBX1
positive patients, low hypodiploidy karyotype, CNS involve-
ment), considering the similar clinical outcome observed for
this heterogeneous group of patients. Globally considered,
these studies all suggest that patients with t(4;11)(q21;q23)/
MLL-AF4 positive ALL have a poor clinical outcome com-
pared to others non-high-risk patients and are potential can-
didates for postinduction intensiﬁcation with HSCT in pres-
enceofanHLA-matchedfamilydonor.However,contrasting
dataaboutthebest therapeuticapproachofthis ALLsubtype
have been reported. Results from MRC UKALLXII/ECOG
2993 trial [30] showed that t(4;11) alteration still identiﬁed
a cohort of patients with poor clinical outcome, despite the
treatment intensiﬁcation with HSCT in ﬁrst CR, due in part
to high incidence of relapse after HSCT and in part to deaths
in CR for complications related to transplant. By contrast,
data from the LALA-94 study suggest that postinduction in-
tensiﬁcation with HSCT in t(4;11)/MLL-AF4 positive pa-
tients was associated with a signiﬁcantly improved DFS with
respect to others patients and that this therapeutic strategy
results in a similar clinical outcome in terms of DFS and OS
inbothstandardandnonPhiladelphia-positivehigh-riskpa-
tients [38]. The advantage of HSCT in this setting of patients
has been demonstrated in GMALL 04/89 study; indeed, in
this study in which HSCT was planned in ﬁrst CR as inten-
siﬁcation after consolidation treatment, no diﬀerences in
terms of both probability of OS and probability of continu-
ous complete remission (CCR) have been observed between
MLL-AF4 positive and negative adult ALL patients [33].
Considering all these studies, due to limited number of
adult patients with this chromosomal aberration, it is not
possible at present to deﬁnitively establish the real role of
intensiﬁcation treatment with HSCT. In general, the low
occurrenceofleukemiarelapseinpatients undergoingHSCT
could be a indirect evidence of advantage of this treatment
strategy, but the high incidence of fatal complications trans-
plant-related may be responsible of the lack of OS improve-
ment. Moreover, deﬁnitive results of MRC UKALLXII/
ECOG E2993 trial have shown interesting results about the
roleofHSCTinALL.Thedonorversusnodonoranalysisde-
monstrated a statistically signiﬁcant 5-year OS improvement
only in standard risk adult patients undergoing intensiﬁca-
tion with HSCT in ﬁrst CR but not in high-risk patients, in
whichanincreaseintransplant-relatedmortalitywasobserv-
ed[50].Theseﬁndingsarepotentiallyabletochangetheuni-
versally accepted idea about the HSCT role as intensiﬁcation
treatment in high-risk ALL patients. Unfortunately, no sub-
analysis on cytogenetic risk stratiﬁcation was performed in
this study, because patients at diagnosis were not stratiﬁed
according to cytogenetic results with the exclusion of Phila-
delphia-chromosome positive patients.
However, also considering the similar results recently ob-
tained in Philadelphia-negative ALL patients undergoing
HSCT both from an HLA-matched family and from a high-
quality matched unrelated donor [51], the European Group
for Blood and Marrow Transplantation (EBMT) guidelines
consider HSCT from a sibling donor or from a well-matched
unrelated donor as a standard of care in adult patients with
high-risk ALL [52].
The decision to intensify consolidation treatment in ALL
can be facilitated by the MRD assessment in ALL sub-types
expressing speciﬁc chromosome aberrations leading to for-
mation of fusion genes. In particular, the ﬁrst recognized
method monitoring MRD was the detection of fusion gene
levels expression by Polymerase Chain Reaction (PCR) [53].
So far, several studies have supported the role of MRD moni-
toring using molecular PCR-based methods; all these studies
show a high percentage of leukemia relapse in patients with
ar e s u l ta b o v e1 0 −4 or 0.01% MRD after induction or con-
solidation therapy [35, 54, 55]. As for MRD monitoring
using speciﬁc probes for MLL-AF4, there are only limited
published observations; in a prospective study of the
GIMEMAgroup,MRDpositivityafterconsolidationtherapy
in about 25 consecutive patients with t(4;11)/MLL-AF4 pos-
itive ALL, signiﬁcantly correlates with a higher cumulative
incidence of leukemia relapse and an inferior OS. Moreover,
all patients with a persistent or reconverted PCR-positivity
status after consolidation subsequently experienced a hema-
tologic relapse of the disease [56].
4. Conclusions
t(4;11)(q21;q23)/MLL-AF4positiveadultALLremainsanat-
tractive leukemic subtype because of special pathogenetic
and clinical aspects with respect to the other ALL forms.
PrognosisofthisformofALLinadultspatientsremainspoor
despite several ongoing clinical and biological studies to im-
proveclinicaloutcome.Oneofthemostimportantquestions
in this setting remains the role of HSCT as consolidation
treatment in ﬁrst CR; even though this approach is the most
used [52, 57], data obtained by international cooperative
groups worldwide are controversial.
In our opinion, HSCT from an HLA-matched family or
high-quality unrelated donor remains a valid strategy for
treatment intensiﬁcation in ﬁrst CR but this procedure, con-Advances in Hematology 7
sidering the high incidence of transplant-related mortality,
should be performed primarily in those patients who have
molecularMRDpositivityafterconsolidationtherapy.More-
over, a possible strategy to improve the clinical outcome of
these patients could be the use of a more eﬀective induction-
consolidationtherapywiththeaimofreachingthemolecular
MRD negativity after consolidation therapy. To achieve this
goal, the use of more aggressive pediatric-like regimens with
higher dose of nonmyeloablative drugs can be an option. In
the absence of speciﬁc recommendations and considering all
thepublishedstudies,itisouropinionthat,inpatientswitha
negativeMRD,consideringtherelativelylowriskofleukemia
relapse, a treatment intensiﬁcation with HSCT should be
performed only in case of reappearance of a PCR-positivity
during the maintenance treatment or during the follow-up,
even in absence of a clear hematologic relapse, as is currently
recommended for acute promyelocytic leukemia.
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